Fennec Pharmaceuticals Presents Pedmark Data in Head and Neck Cancer Study

Fennec Pharmaceuticals announced new real world data supporting potential use of Pedmark in adults with head and neck cancers were presented as a digital poster at the 2026 Multidisciplinary Head and Neck Cancers Symposium, MHNCS, in Palm Desert, CA from February 19 - 21, 2026. Findings from a multi-institutional retrospective review of 15 adults with head and neck cancers showed that Pedmark could be safely given greater than or equal to six hours after cisplatin dosing and was easy to incorporate into the real-world care plan for adults with HNC. This strict post-cisplatin timing is a validated approach intended to preserve cisplatin antitumor activity and no disruption to curative-intent cisplatin-based treatment delivery was observed as part of the study review. The study's primary endpoint evaluated feasibility, defined by timing adherence and operational metrics, including administration setting and chair time for infusion-center dosing. Secondary endpoints included infusion-related events, need for antiemetic escalation, and completion of on-treatment and post-treatment audiology assessments.